JP2016530889A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2016530889A5 JP2016530889A5 JP2016542337A JP2016542337A JP2016530889A5 JP 2016530889 A5 JP2016530889 A5 JP 2016530889A5 JP 2016542337 A JP2016542337 A JP 2016542337A JP 2016542337 A JP2016542337 A JP 2016542337A JP 2016530889 A5 JP2016530889 A5 JP 2016530889A5
- Authority
- JP
- Japan
- Prior art keywords
- polypeptide
- hbv
- cells
- cdrs
- huh7
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 108090000765 processed proteins & peptides Proteins 0.000 claims description 42
- 229920001184 polypeptide Polymers 0.000 claims description 40
- 102000004196 processed proteins & peptides Human genes 0.000 claims description 40
- 239000000203 mixture Substances 0.000 claims description 17
- 239000000427 antigen Substances 0.000 claims description 14
- 108091007433 antigens Proteins 0.000 claims description 14
- 102000036639 antigens Human genes 0.000 claims description 14
- 206010073071 hepatocellular carcinoma Diseases 0.000 claims description 10
- 201000007270 liver cancer Diseases 0.000 claims description 7
- 208000014018 liver neoplasm Diseases 0.000 claims description 7
- 238000006471 dimerization reaction Methods 0.000 claims description 5
- 239000012634 fragment Substances 0.000 claims description 5
- 239000012642 immune effector Substances 0.000 claims description 5
- 229940121354 immunomodulator Drugs 0.000 claims description 5
- 101000914514 Homo sapiens T-cell-specific surface glycoprotein CD28 Proteins 0.000 claims description 3
- 102100027213 T-cell-specific surface glycoprotein CD28 Human genes 0.000 claims description 3
- 108010047041 Complementarity Determining Regions Proteins 0.000 claims 10
- 208000015181 infectious disease Diseases 0.000 claims 9
- 239000003446 ligand Substances 0.000 claims 5
- 125000003275 alpha amino acid group Chemical group 0.000 claims 3
- 208000019425 cirrhosis of liver Diseases 0.000 claims 3
- 231100000844 hepatocellular carcinoma Toxicity 0.000 claims 3
- 238000000034 method Methods 0.000 claims 3
- 125000006850 spacer group Chemical group 0.000 claims 3
- 208000024891 symptom Diseases 0.000 claims 3
- 102100032852 Natural cytotoxicity triggering receptor 3 Human genes 0.000 claims 2
- 238000000338 in vitro Methods 0.000 claims 2
- 101710098119 Chaperonin GroEL 2 Proteins 0.000 claims 1
- 108010087819 Fc receptors Proteins 0.000 claims 1
- 102000009109 Fc receptors Human genes 0.000 claims 1
- 206010016654 Fibrosis Diseases 0.000 claims 1
- 101000872838 Hepatitis B virus genotype C subtype adr (isolate China/NC-1/1988) Small envelope protein Proteins 0.000 claims 1
- 101000917858 Homo sapiens Low affinity immunoglobulin gamma Fc region receptor III-A Proteins 0.000 claims 1
- 101000917839 Homo sapiens Low affinity immunoglobulin gamma Fc region receptor III-B Proteins 0.000 claims 1
- 101001109501 Homo sapiens NKG2-D type II integral membrane protein Proteins 0.000 claims 1
- 101000589307 Homo sapiens Natural cytotoxicity triggering receptor 3 Proteins 0.000 claims 1
- 101000581981 Homo sapiens Neural cell adhesion molecule 1 Proteins 0.000 claims 1
- 101000851370 Homo sapiens Tumor necrosis factor receptor superfamily member 9 Proteins 0.000 claims 1
- 108060003951 Immunoglobulin Proteins 0.000 claims 1
- 102100029185 Low affinity immunoglobulin gamma Fc region receptor III-B Human genes 0.000 claims 1
- 102100022680 NKG2-D type II integral membrane protein Human genes 0.000 claims 1
- 108010004222 Natural Cytotoxicity Triggering Receptor 3 Proteins 0.000 claims 1
- 102100027347 Neural cell adhesion molecule 1 Human genes 0.000 claims 1
- 102100022153 Tumor necrosis factor receptor superfamily member 4 Human genes 0.000 claims 1
- 101710165473 Tumor necrosis factor receptor superfamily member 4 Proteins 0.000 claims 1
- 102100036856 Tumor necrosis factor receptor superfamily member 9 Human genes 0.000 claims 1
- 230000007882 cirrhosis Effects 0.000 claims 1
- 230000001747 exhibiting effect Effects 0.000 claims 1
- 238000009472 formulation Methods 0.000 claims 1
- 102000018358 immunoglobulin Human genes 0.000 claims 1
- 239000013631 noncovalent dimer Substances 0.000 claims 1
- 102000039446 nucleic acids Human genes 0.000 claims 1
- 108020004707 nucleic acids Proteins 0.000 claims 1
- 150000007523 nucleic acids Chemical class 0.000 claims 1
- 239000008194 pharmaceutical composition Substances 0.000 claims 1
- 238000006467 substitution reaction Methods 0.000 claims 1
- 210000004027 cell Anatomy 0.000 description 106
- 210000003819 peripheral blood mononuclear cell Anatomy 0.000 description 53
- 230000000638 stimulation Effects 0.000 description 21
- 230000000694 effects Effects 0.000 description 18
- 230000004083 survival effect Effects 0.000 description 17
- 239000010432 diamond Substances 0.000 description 16
- 108060008682 Tumor Necrosis Factor Proteins 0.000 description 13
- 102000000852 Tumor Necrosis Factor-alpha Human genes 0.000 description 13
- 108010002350 Interleukin-2 Proteins 0.000 description 12
- 210000001744 T-lymphocyte Anatomy 0.000 description 12
- 238000012413 Fluorescence activated cell sorting analysis Methods 0.000 description 8
- 102100035133 Lysosome-associated membrane glycoprotein 1 Human genes 0.000 description 8
- 101710116782 Lysosome-associated membrane glycoprotein 1 Proteins 0.000 description 8
- 238000003501 co-culture Methods 0.000 description 7
- 230000009089 cytolysis Effects 0.000 description 7
- 238000002784 cytotoxicity assay Methods 0.000 description 7
- 231100000263 cytotoxicity test Toxicity 0.000 description 7
- 230000028327 secretion Effects 0.000 description 6
- 239000006228 supernatant Substances 0.000 description 6
- MZOFCQQQCNRIBI-VMXHOPILSA-N (3s)-4-[[(2s)-1-[[(2s)-1-[[(1s)-1-carboxy-2-hydroxyethyl]amino]-4-methyl-1-oxopentan-2-yl]amino]-5-(diaminomethylideneamino)-1-oxopentan-2-yl]amino]-3-[[2-[[(2s)-2,6-diaminohexanoyl]amino]acetyl]amino]-4-oxobutanoic acid Chemical compound OC[C@@H](C(O)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CCCN=C(N)N)NC(=O)[C@H](CC(O)=O)NC(=O)CNC(=O)[C@@H](N)CCCCN MZOFCQQQCNRIBI-VMXHOPILSA-N 0.000 description 5
- 102100037850 Interferon gamma Human genes 0.000 description 4
- 108010074328 Interferon-gamma Proteins 0.000 description 4
- 239000003550 marker Substances 0.000 description 4
- 238000010186 staining Methods 0.000 description 4
- 230000035899 viability Effects 0.000 description 4
- 102000000588 Interleukin-2 Human genes 0.000 description 3
- 206010028980 Neoplasm Diseases 0.000 description 3
- 230000006037 cell lysis Effects 0.000 description 3
- 241000699670 Mus sp. Species 0.000 description 2
- 230000010056 antibody-dependent cellular cytotoxicity Effects 0.000 description 2
- 238000003556 assay Methods 0.000 description 2
- 230000015572 biosynthetic process Effects 0.000 description 2
- 230000001413 cellular effect Effects 0.000 description 2
- 230000003247 decreasing effect Effects 0.000 description 2
- 238000001514 detection method Methods 0.000 description 2
- 229910003460 diamond Inorganic materials 0.000 description 2
- 231100000673 dose–response relationship Toxicity 0.000 description 2
- 230000008030 elimination Effects 0.000 description 2
- 238000003379 elimination reaction Methods 0.000 description 2
- 230000001960 triggered effect Effects 0.000 description 2
- 102000004127 Cytokines Human genes 0.000 description 1
- 108090000695 Cytokines Proteins 0.000 description 1
- 206010073069 Hepatic cancer Diseases 0.000 description 1
- 241001465754 Metazoa Species 0.000 description 1
- 230000004913 activation Effects 0.000 description 1
- 230000020411 cell activation Effects 0.000 description 1
- 230000003833 cell viability Effects 0.000 description 1
- 238000003570 cell viability assay Methods 0.000 description 1
- 239000012636 effector Substances 0.000 description 1
- 210000002472 endoplasmic reticulum Anatomy 0.000 description 1
- 230000007717 exclusion Effects 0.000 description 1
- 230000004927 fusion Effects 0.000 description 1
- 238000004519 manufacturing process Methods 0.000 description 1
- 239000011259 mixed solution Substances 0.000 description 1
- 210000000822 natural killer cell Anatomy 0.000 description 1
- 238000005549 size reduction Methods 0.000 description 1
- 238000007920 subcutaneous administration Methods 0.000 description 1
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP13184635.4 | 2013-09-16 | ||
| EP13184635 | 2013-09-16 | ||
| PCT/EP2014/069675 WO2015036606A1 (en) | 2013-09-16 | 2014-09-16 | Bi- or multispecific polypeptides binding immune effector cell surface antigens and hbv antigens for treating hbv infections and associated conditions |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2016530889A JP2016530889A (ja) | 2016-10-06 |
| JP2016530889A5 true JP2016530889A5 (cg-RX-API-DMAC7.html) | 2019-04-11 |
| JP6599338B2 JP6599338B2 (ja) | 2019-10-30 |
Family
ID=49165642
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2016542337A Active JP6599338B2 (ja) | 2013-09-16 | 2014-09-16 | Ｈｂｖ感染および関連症状の治療のための免疫エフェクター細胞表面抗原およびｈｂｖ抗原結合性の二重特異性または多重特異性ポリペプチド |
Country Status (8)
| Country | Link |
|---|---|
| US (2) | US10059767B2 (cg-RX-API-DMAC7.html) |
| EP (1) | EP3046938B1 (cg-RX-API-DMAC7.html) |
| JP (1) | JP6599338B2 (cg-RX-API-DMAC7.html) |
| CN (2) | CN105636982B (cg-RX-API-DMAC7.html) |
| CA (1) | CA2924252C (cg-RX-API-DMAC7.html) |
| ES (1) | ES2773306T3 (cg-RX-API-DMAC7.html) |
| RU (1) | RU2671089C2 (cg-RX-API-DMAC7.html) |
| WO (1) | WO2015036606A1 (cg-RX-API-DMAC7.html) |
Families Citing this family (28)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CA2747011C (en) | 2008-12-18 | 2018-06-19 | Dana-Farber Cancer Institute, Inc. | Nkg2d-fc for immunotherapy |
| US10059767B2 (en) | 2013-09-16 | 2018-08-28 | Helmholtz Zentrum München—Deutsches Forschungszentrum für Gesundheit und Umwelt (GmbH) | Means and methods for treating HBV infection and associated conditions |
| EP3271387B1 (en) * | 2015-03-16 | 2023-12-06 | Helmholtz Zentrum München - Deutsches Forschungszentrum für Gesundheit und Umwelt (GmbH) | Trispecific binding molecules for treating hbv infection and associated conditions |
| CN106349391A (zh) * | 2015-07-17 | 2017-01-25 | 中国科学院深圳先进技术研究院 | Hbv特异性双靶向抗体及其制备方法和应用、含该双靶向抗体表达盒的微环dna及应用 |
| JP7037480B2 (ja) * | 2015-11-13 | 2022-03-16 | デイナ ファーバー キャンサー インスティチュート，インコーポレイテッド | がんの免疫療法のためのｎｋｇ２ｄ－ｉｇ融合タンパク質 |
| CN105505872B (zh) * | 2016-02-16 | 2019-01-15 | 广州赛莱拉干细胞科技股份有限公司 | 一种致敏nk细胞的方法及组合物 |
| CN107129537A (zh) * | 2016-02-29 | 2017-09-05 | 北京赛诺泰生物科技有限公司 | 抗乙型肝炎病毒的免疫反应性细胞 |
| WO2018064611A1 (en) * | 2016-09-30 | 2018-04-05 | Baylor College Of Medicine | Antibody based gene therapy with tissue-directed expression |
| US11219646B2 (en) * | 2016-09-30 | 2022-01-11 | Baylor College Of Medicine | Chimeric antigen receptor therapy with reduced cytotoxicity for viral disease |
| KR20250089564A (ko) | 2017-02-08 | 2025-06-18 | 드래곤플라이 쎄라퓨틱스, 인크. | 천연 킬러 세포의 활성화를 위한 다중-특이적 결합 단백질 및 암 치료에서의 그의 치료적 용도 |
| KR20190120782A (ko) | 2017-02-20 | 2019-10-24 | 드래곤플라이 쎄라퓨틱스, 인크. | Her2, nkg2d 및 cd16에 결합하는 단백질 |
| PE20210375A1 (es) | 2018-02-08 | 2021-03-02 | Dragonfly Therapeutics Inc | Terapia de combinacion del cancer que incluye proteinas de union multiespecificas que activan a las celulas asesinas naturales |
| CA3090244A1 (en) | 2018-02-08 | 2019-08-15 | Dragonfly Therapeutics, Inc. | Antibody variable domains targeting the nkg2d receptor |
| CN112119093A (zh) | 2018-02-20 | 2020-12-22 | 蜻蜓治疗公司 | 结合cd33、nkg2d和cd16的多特异性结合蛋白和使用方法 |
| EA202091888A1 (ru) | 2018-08-08 | 2020-10-23 | Драгонфлай Терапьютикс, Инк. | Вариабельные домены антител, нацеленные на рецептор nkg2d |
| CA3108427A1 (en) | 2018-08-08 | 2020-02-13 | Dragonfly Therapeutics, Inc. | Multi-specific binding proteins that bind bcma, nkg2d and cd16, and methods of use |
| BR112021002276A2 (pt) | 2018-08-08 | 2021-05-04 | Dragonfly Therapeutics, Inc. | proteínas de ligação a nkg2d, cd16 e um antígeno associado ao tumor |
| CN109265559B (zh) * | 2018-09-25 | 2021-12-07 | 山东兴瑞生物科技有限公司 | 嵌合抗原受体、其制备方法、利用其修饰的nk细胞及治疗hbv感染的应用 |
| SG11202105948TA (en) * | 2018-12-19 | 2021-07-29 | Regeneron Pharma | Bispecific anti-muc16 x anti-cd28 antibodies and uses thereof |
| GB201904328D0 (en) * | 2019-03-28 | 2019-05-15 | Immunocore Ltd | Specific binding molecules |
| KR102503349B1 (ko) | 2019-05-14 | 2023-02-23 | 프로벤션 바이오, 인코포레이티드 | 제1형 당뇨병을 예방하기 위한 방법 및 조성물 |
| US12157771B2 (en) | 2020-05-06 | 2024-12-03 | Dragonfly Therapeutics, Inc. | Proteins binding NKG2D, CD16 and CLEC12A |
| WO2021252917A2 (en) | 2020-06-11 | 2021-12-16 | Provention Bio, Inc. | Methods and compositions for preventing type 1 diabetes |
| WO2022081529A1 (en) * | 2020-10-12 | 2022-04-21 | Greffex, Inc. | Antibody constructs to target t cell responses to sars-cov protein expressing cells, their design and uses |
| CN112592902B (zh) * | 2020-12-16 | 2022-03-29 | 熊猫乳品集团股份有限公司 | 一种生物活性肽aseppvldvkrpflc及其制备方法和应用 |
| WO2022187539A1 (en) | 2021-03-03 | 2022-09-09 | Dragonfly Therapeutics, Inc. | Methods of treating cancer using multi-specific binding proteins that bind nkg2d, cd16 and a tumor-associated antigen |
| CN114573705B (zh) * | 2022-03-17 | 2024-05-14 | 杭州师范大学 | 特异性启动抗乙型肝炎病毒t细胞免疫的双特异性抗体及其应用 |
| KR20250042205A (ko) * | 2022-06-27 | 2025-03-26 | 에스씨지 셀 테라피 피티이. 리미티드 | HBV 표면 항원 (HBsAg) 및 CD3에 대한 이중 특이적 항체 및 이의 용도 |
Family Cites Families (13)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB8928874D0 (en) * | 1989-12-21 | 1990-02-28 | Celltech Ltd | Humanised antibodies |
| EP1311530A4 (en) * | 2000-08-03 | 2004-10-06 | Wim-Van Schooten | PRODUCTION OF HUMANIZED ANTIBODIES IN TRANSGENIC ANIMALS |
| CN1294148C (zh) | 2001-04-11 | 2007-01-10 | 中国科学院遗传与发育生物学研究所 | 环状单链三特异抗体 |
| FR2844513B1 (fr) * | 2002-09-13 | 2007-08-03 | Lab Francais Du Fractionnement | Anticorps pour adcc et induisant la production de cytokines. |
| US7534604B2 (en) * | 2004-01-16 | 2009-05-19 | Regeneron Pharmaceuticals, Inc. | Fusion polypeptides capable of activating receptors |
| CN100376599C (zh) | 2004-04-01 | 2008-03-26 | 北京安波特基因工程技术有限公司 | 基因工程重组抗cea抗cd3抗cd28线性单链三特异抗体 |
| PT2520590T (pt) * | 2007-04-03 | 2018-11-14 | Amgen Res Munich Gmbh | Domínio de ligação específico de espécies cruzadas |
| RS53008B2 (sr) * | 2007-04-03 | 2022-12-30 | Amgen Res Munich Gmbh | Interspecijski specifičan cd3-epsilon vezujući domen |
| WO2011057124A1 (en) * | 2009-11-06 | 2011-05-12 | Transtarget, Inc. | Polyclonal bispecific antibody compositions and method of use |
| WO2012156430A1 (en) * | 2011-05-17 | 2012-11-22 | Trion Research Gmbh | Vaccine preparation containing trifunctional antibodies with antigen immunogenicity enhancer properties |
| EP2524699A1 (en) * | 2011-05-17 | 2012-11-21 | Trion Research GmbH | Vaccine preparation containing trifunctional antibodies with antigen immunogenicity enhancer properties |
| EP2797629A4 (en) * | 2011-12-28 | 2015-09-30 | Novelmed Therapeutics Inc | AGLYCOSYLATED HUMAN ANTIBODY AND FUSION PROTEIN AND USES THEREOF |
| US10059767B2 (en) | 2013-09-16 | 2018-08-28 | Helmholtz Zentrum München—Deutsches Forschungszentrum für Gesundheit und Umwelt (GmbH) | Means and methods for treating HBV infection and associated conditions |
-
2014
- 2014-09-16 US US15/021,916 patent/US10059767B2/en active Active
- 2014-09-16 JP JP2016542337A patent/JP6599338B2/ja active Active
- 2014-09-16 EP EP14771250.9A patent/EP3046938B1/en active Active
- 2014-09-16 ES ES14771250T patent/ES2773306T3/es active Active
- 2014-09-16 CN CN201480050976.8A patent/CN105636982B/zh active Active
- 2014-09-16 CA CA2924252A patent/CA2924252C/en active Active
- 2014-09-16 CN CN202010449532.9A patent/CN111606998B/zh active Active
- 2014-09-16 WO PCT/EP2014/069675 patent/WO2015036606A1/en not_active Ceased
- 2014-09-16 RU RU2016114504A patent/RU2671089C2/ru active
-
2018
- 2018-08-24 US US16/112,431 patent/US10730943B2/en active Active
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2016530889A5 (cg-RX-API-DMAC7.html) | ||
| Duan et al. | The BCMA-targeted fourth-generation CAR-T cells secreting IL-7 and CCL19 for therapy of refractory/recurrent multiple myeloma | |
| CN112437776B (zh) | 间皮素和cd137结合分子 | |
| US9828432B2 (en) | Cancer treatment and monitoring methods using OX40 agonists | |
| ES2754557T3 (es) | Combinación de un anticuerpo CD30XCD16A con un anticuerpo antagonista anti-PD-1 para terapia | |
| JP2018501197A5 (cg-RX-API-DMAC7.html) | ||
| JP2020526211A5 (cg-RX-API-DMAC7.html) | ||
| KR20210031479A (ko) | Cd137 및 ox40에 결합하는 항체 분자 | |
| RU2019134352A (ru) | Новые биспецифические антигенсвязывающие молекулы, обладающие способностью специфически связываться с cd40 и fap | |
| JP2018508483A5 (cg-RX-API-DMAC7.html) | ||
| RU2013106217A (ru) | Гибридный белок из антитела против мнс и противовирусного цитокина | |
| JP2018512170A5 (cg-RX-API-DMAC7.html) | ||
| CN116003608A (zh) | 拮抗性cd40单克隆抗体及其用途 | |
| JP2016527286A5 (cg-RX-API-DMAC7.html) | ||
| HK1254289A1 (zh) | 调控免疫反应的方法及抗体 | |
| WO2020043683A1 (en) | Combination therapies comprising cd137/her2 bispecific agents and pd-1 axis inhibitors and uses thereof | |
| JP2022523804A (ja) | がんの処置における増強された有効性のためのｉｌ－４／ｉｌ－１３経路阻害剤 | |
| JP2020532304A5 (cg-RX-API-DMAC7.html) | ||
| US20240011046A1 (en) | Oncolytic viruses encoding recombinant transforming growth factor (tgf)-beta monomers and uses thereof | |
| Zhang et al. | Engineering nano‐clustered multivalent agonists to cross‐link TNF receptors for cancer therapy | |
| Long et al. | HLA-class II restricted TCR targeting human papillomavirus type 18 E7 induces solid tumor remission in mice | |
| Mendoza-Valderrey et al. | Next generation immuno-oncology strategies: unleashing NK cells activity | |
| CN116457018A (zh) | Herv-k抗体治疗剂 | |
| US20240409653A1 (en) | Multispecific binding agents against pd-l1 and cd137 in combination with anti pd-1 antibodies for treating cancers | |
| Palmeri et al. | Tregs constrain CD8+ T cell priming required for curative intratumorally anchored anti-4-1BB immunotherapy |